Human dendritic cells transduced with herpes simplex virus amplicons encoding human immunodeficiency virus type 1 (HIV-1) gp120 elicit adaptive immune responses from human cells engrafted into NOD/SCID mice and confer partial protection against HIV-1 challenge

Journal of Virology

Volumn 79, Issue 4, 2005, Pages 2124-2132

  Gorantla, Santhi ^a   Santos, Kathlyn ^b   Meyer, Vakara ^a   Dewhurst, Stephen ^b   Bowers, William J ^b   Federoff, Howard J ^b   Gendelman, Howard E ^a,c   Poluektova, Larisa ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

AMPLICON; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODY FORMATION; DEFECTIVE VIRUSES; DENDRITIC CELLS; DNA, VIRAL; GENETIC VECTORS; HELPER VIRUSES; HERPESVIRUS 1, HUMAN; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; MICE; MICE, INBRED NOD; MICE, SCID; MODELS, ANIMAL; TRANSDUCTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA; HERPES; HUMAN HERPESVIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES; SIMPLEXVIRUS;

EID: 13444302296     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.4.2124-2132.2005     Document Type: Article

References (62)

1. Achour, A., O. Picard, J. P. Mbika, A. Willer, R. Snart, B. Bizzini, C. Carelli, A. Burny, and D. Zagury. 1993. Envelope protein and p18(IIIB) peptide recognized by cytotoxic T lymphocytes from humans immunized with human immunodeficiency virus envelope. Vaccine 11:609-701.
2. Ahmad, K. 2003. High hopes for HIV vaccine. Lancet Infect. Dis. 3:62.
3. Ahonen, C. L., S. J. Gihson, R. M. Smith, L. K. Pederson, J. M. Lindh, M. A. Tomai, and J. P. Vasilakos. 1999. Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848. Cell Immunol. 197:62-72.
4. Alexander-Miller, M. A., K. C. Parker, T. Tsukui, C. D. Pendleton, J. E. Coligan, and J. A. Berzofsky. 1996. Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-envelope protein to human cytotoxic T lymphocytes. Int. Immunol. 8:641-649.
5. Banchereau, J., J. Fay, V. Pascual, and A. K. Palucka. 2003. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Novartis Found. Symp. 252:226-235.
6. Bombil, F., J. P. Kints, J. M. Scheiff, H. Bazin, and D. Latinne. 1996. A promising model of primary human immunization in human-scid mouse. Immunobiology 195:360-375.
7. Bower, J. F., X. Yang, J. Sodroski, and T. M. Ross. 2004. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. J. Virol. 78:4710-4719.
8. Brown, K., W. Gao, S. Alber, A. Trichel, M. Murphey-Corb, S. C. Watkins, A. Gambotto, and S. M. Barratt-Boyes. 2003. Adenovirus-transduced dendritic cells injected into skin or lymph node prime potent simian immunodeficiency virus-specific T cell immunity in monkeys. J. Immunol. 171:6875-6882.
9. Calarota, S. A., and D. B. Weiner. 2003. Present status of human HIV vaccine development. Aids 17(Suppl. 4):S73-S84.
10. Chakrabarti, B. K., W. P. Kong, B. Y. Wu, Z. Y. Yang, J. Friborg, X. Ling, S. R. King, D. C. Montefiori, and G. J. Nabel. 2002. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J. Virol. 76:5357-5368.
11. Chargui, J., D. Dye, J. Blomberg, C. Desgranges, and J. L. Touraine. 1995. The humanized severe combined immunodeficient mouse as a model for primary human humoral response against HIV1 peptides. J. Immunol. Methods 181:91-100.
12. Emini, E. A., and W. C. Koff. 2004. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope. Science 304:1913-1914.
13. Fais, S., C. Lapenta, S. M. Santini, M. Spada, S. Parlato, M. Logozzi, P. Rizza, and F. Belardelli. 1999. Human immunodeficiency virus type 1 strains R5 and X4 induce different pathogenic effects in hu-PBL-SCID mice, depending on the state of activation/differentiation of human target cells at the time of primary infection. J. Virol. 73:6453-6459.
14. Gardner, M. B., and P. A. Luciw. 1989. Animal models of AIDS. FASEB J. 3:2593-2606.
15. Gendelman, H. E., J. M. Orenstein, M. A. Martin, C. Ferrua, R. Mitra, T. Phipps, L. A. Wahl, H. C. Lane, A. S. Fauci, D. S. Burke, et al. 1988. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J. Exp. Med. 167:1428-1441.
16. Gilliam, B. L., and R. R. Redfield. 2003. Therapeutic HIV vaccines. Curr. Top. Med. Chem. 3:1536-1553.
17. Greiner, D. L., L. D. Shultz, J. Yates, M. C. Appel, G. Perdrizet, R. M. Hesselton, I. Schweitzer, W. G. Beamer, K. L. Shultz, S. C. Pelsue, and et al. 1995. Improved engraftment of human spleen cells in NOD/LtSz-scid/scid mice as compared with C.B-17-scid/scid mice. Am. J. Pathol. 146:888-902.
18. Hesselton, R. M., R. A. Koup, M. A. Cromwell, B. S. Graham, M. Johns, and J. L. Sullivan. 1993. Human peripheral blood xenografts in the SCID mouse: characterization of immunologic reconstitution. J. Infect. Dis. 168:630-640.
19. Hewer, R., and D. Meyer. 2003. Peptide immunogens based on the envelope region of HIV-1 are recognized by HIV/AIDS patient polyclonal antibodies and induce strong humoral immune responses in mice and rabbits. Mol. Immunol. 40:327-335.
20. Hocknell, P. K., R. D. Wiley, X. Wang, T. G. Evans, W. J. Bowers, T. Hanke, H. J. Federoff, and S. Dewhurst. 2002. Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses. J. Virol. 76:5565-5580.
21. Joag, S. V. 2000. Primate models of AIDS. Microbes Infect. 2:223-229.
22. Johnston, M. I. 2000. The role of nonhuman primate models in AIDS vaccine development. Mol. Med. Today 6:267-270.
23. Joshi, S. S., U. E. Vu, T. R. Lovgren, M. Lorkovic, W. Patel, G. L. Todd, C. Kuszynski, B. J. Joshi, and H. P. Dave. 2002. Comparison of phenotypic and functional dendritic cells derived from human umbilical cord blood and peripheral blood mononuclear cells. J. Hematother. Stem Cell Res. 11:337-347.
24. Kalter, D. C., H. E. Gendelman, and M. S. Meltzer. 1991. Inhibition of human immunodeficiency virus infection in monocytes by monoclonal antibodies against leukocyte adhesion molecules. Immunol. Lett. 30:219-227.
25. Kaur, A., and R. P. Johnson. 2003. HIV pathogenesis and vaccine development. Top. HIV Med. 11:76-85.
26. Koyanagi, Y., Y. Tanaka, J. Kira, M. Ito, K. Hioki, N. Misawa, Y. Kawano, K. Yamasaki, R. Tanaka, Y. Suzuki, Y. Ueyama, E. Terada, T. Tanaka, M. Miyasaka T. Kobayashi, Y. Kumazawa, and N. Yamamoto. 1997. Primary human immunodeficiency virus type 1 viremia and central nervous system invasion in a novel hu-PBL-immunodeficient mouse strain. J. Virol. 71:2417-2424.
27. LaFranco-Scheuch, L., K. Abel, N. Makori, K. Rothaeusler, and C. J. Miller. 2004. High beta-chemokine expression levels in lymphoid tissues of simian/human immunodeficiency virus 89.6-vaccinated rhesus macaques are associated with uncontrolled replication of simian immunodeficiency virus challenge inoculum. J. Virol. 78:6399-6408.
28. Lapenta, C, S. M. Santini, M. Logozzi, M. Spada, M. Andreotti, T. Di Pucchio, S. Parlato, and F. Belardelli. 2003. Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J. Exp. Med. 198:361-367.
29. Lu, W., X. Wu, Y. Lu, W. Guo, and J. M. Andrieu. 2003. Therapeutic dendritic-cell vaccine for simian AIDS. Nat. Med. 9:27-32.
30. Marovich, M. A., J. R. Mascola, M. A. Eller, M. K. Louder, P. A. Caudrelier, R. El-Habib, S. Ratto-Kim, J. H. Cox, J. R. Currier, B. L. Levine, C. H. June, W. B. Bernstein, M. L. Robb, B. Schuler-Thurner, R. M. Steinman, D. L. Birx, and S. Schlesinger-Frankel. 2002. Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells. J. Infect. Dis. 186:1242-1252.
31. Matano, T., M. Kobayashi, H. Igarashi, A. Takeda, H. Nakamura, M. Kano, C. Sugimoto, K. Mori, A. Iida, T. Hirata, M. Hasegawa, T. Yuasa, M. Miyazawa, Y. Takahashi, M. Yasunami, A. Kimura, D. H. O'Connor, D. I. Watkins, and Y. Nagai. 2004. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J. Exp. Med. 199:1709-1718.
32. McCluskie, M. J., C. L. Brazolot Millan, R. A. Gramzinski, H. L. Robinson, J. C. Santoro, J. T. Fuller, G. Widera, J. R. Haynes, R. H. Purcell, and H. L. Davis. 1999. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol. Med. 5:287-300.
33. McKinney, D. M., D. A. Lewinsohn, S. R. Riddell, P. D. Greenberg, and D. E. Mosier. 1999. The antiviral activity of HIV-specific CD8+ CTL clones is limited by elimination due to encounter with HIV-infected targets. J. Immunol. 163:861-867.
34. McMichael, A. J., and T. Hanke. 2003. HIV vaccines 1983-2003. Nat. Med. 9:874-880.
35. Mikloska, Z., L. Bosnjak, and A. L. Cunningham. 2001. Immature monocyte-derived dendritic cells are productively infected with herpes simplex virus type 1. J. Virol. 75:5958-5964.
36. Mosier, D., and H. Sieburg. 1994. Macrophage-tropic HIV: critical for AIDS pathogenesis? Immunol. Today 15:332-339.
37. Mosier, D. E., R. J. Gulizia, S. M. Baird, D. B. Wilson, D. H. Spector, and S. A. Spector. 1991. Human immunodeficiency virus infection of human-PBL-SCID mice. Science 251:791-794.
38. Mosier, D. E., R. J. Gulizia, P. MacIsaac, B. J. Mathieson, G. Smith, S. L. Hu, L. Corey, and P. Greenberg. 1992. Evaluation of gp160 vaccinees in the hu-PBL-SCID mouse model. AIDS Res. Hum. Retrovir. 8:1387.
39. Mosier, D. E., R. J. Gulizia, P. D. MacIsaac, B. E. Torbett, and J. A. Levy. 1993. Rapid loss of CD4+ T cells in human-PBL-SCID mice by noncytopathic HIV isolates. Science 260:689-692.
40. Nath, B. M., K. E. Schumann, and J. D. Boyer. 2000. The chimpanzee and other non-human-primate models in HIV-1 vaccine research. Trends Microbiol. 8:426-431.
41. Nehete, P. N., R. Gambhira, B. P. Nehete, and K. J. Sastry. 2003. Dendritic cells enhance detection of antigen-specific cellular immune responses by lymphocytes from rhesus macaques immunized with an HIV envelope peptide cocktail vaccine. J. Med. Primatol. 32:67-73.
42. Pollock, P. L., D. R. Germolec, C. E. Comment, G. J. Rosenthal, and M. I. Luster. 1994. Development of human lymphocyte-engrafted SCID mice as a model for immunotoxicity assessment. Fundam. Appl. Toxicol. 22:130-138.
43. Poluektova, L., S. Gorantla, J. Faraci, K. Birusingh, H. Dou, and H. E. Gendelman. 2004. Neuroregulatory events follow adaptive immune-mediated elimination of HIV-1-infected macrophages: studies in a murine model of viral encephalitis. J. Immunol. 172:7610-7617.
44. Poluektova, L. Y., D. H. Munn, Y. Persidsky, and H. E. Gendelman. 2002. Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis. J. Immunol. 168:3941-3949.
45. Rollman, E., J. Hinkula, J. Arteaga, B. Zuber, A. Kjerrstrom, M. Liu, B. Wahren, and K. Ljungberg. 2004. Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies. Gene Ther. 11:1146-1154.
46. Schuitemaker, H. 1994. Macrophage-tropic HIV-1 variants: initiators of infection and AIDS pathogenesis? J. Leukoc. Biol. 56:218-224.
47. Segall, H., I. Lubin H. Marcus, A. Canaan, and Y. Reisner. 1996. Generation of primary antigen-specific human cytotoxic T lymphocytes in human/mouse radiation chimera. Blood 88:721-730.
48. Sena-Esteves, M, Y. Saeki, C. Fraefel, and X. O. Breakefield. 2000. HSV-1 amplicon vectors - simplicity and versatility. Mol. Ther. 2:9-15.
49. Spearman, P. 2003. HIV vaccine development: lessons from the past and promise for the future. Curr. HIV Res. 1:101-120.
50. Steinman, R. M. 2000. The dendritic cell advantage: New focus for immune-based therapies. Drug News Perspect. 13:581-586.
51. Steinman, R. M. 1996. Dendritic cells and immune-based therapies. Exp. Hematol. 24:859-862.
52. Tanaka, T., M. Tsudo, H. Karasuyama, F. Kitamura, T. Kono, M. Hatakeyama, T. Taniguchi, and M. Miyasaka. 1991. A novel monoclonal antibody against murine IL-2 receptor beta-chain. Characterization of receptor expression in normal lymphoid cells and EL-4 cells. J. Immunol. 147:2222-2228.
53. Tary-Lehmann, M., A. Saxon, and P. V. Lehmann. 1995. The human immune system in hu-PBL-SCID mice. Immunol. Today 16:529-533.
54. Thomsen, L. L., P. Topley, M. G. Daly, S. J. Brett, and J. P. Tite. 2004. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 22:1799-1809.
55. Torbett, B. E., G. Picchio, and D. E. Mosier. 1991. hu-PBL-SCID mice: a model for human immune function, AIDS, and lymphomagenesis. Immunol. Rev. 124:139-164.
56. van Kuyk, R., B. E. Torbett, R. J. Gulizia, S. Leath, D. E. Mosier, and S. Koenig. 1994. Cloned human CD8+ cytotoxic T lymphocytes protect human peripheral blood leukocyte-severe combined immunodeficient mice from HIV-1 infection by an HLA-unrestricted mechanism. J. Immunol. 153:4826-4833.
57. Wang, S., C. Fraefel, and X. Breakefield. 2002. HSV-1 amplicon vectors. Methods Enzymol. 346:593-603.
58. Wang, X., R. D. Wiley, T. G. Evans, W. J. Bowers, H. J. Federoff, and S. Dewhurst. 2003. Cellular immune responses to helper-free HSV-1 amplicon particles encoding HIV-1 gp120 are enhanced by DNA priming. Vaccine 21:2288-2297.
59. Warren, J. 2002. Preclinical AIDS vaccine research: survey of SIV, SHIV, and HIV challenge studies in vaccinated nonhuman primates. J. Med. Primatol. 31:237-256.
60. Willis, R. A., W. J. Bowers, M. J. Turner, T. L. Fisher, C. S. Abdul-Alim, D. F. Howard, H. J. Federoff, E. M. Lord, and J. G. Frelinger. 2001. Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice. Hum. Gene Ther. 12:1867-1879.
61. + T-cell origin. J. Virol. 77:8719-8728.
62. Zhan, X., K. S. Slobod, S. Surman, S. A. Brown, C. Coleclough, and J. L. Hurwitz. 2004. Minor components of a multienvelope HIV vaccine are recognized by type-specific T-helper cells. Vaccine 22:1206-1213.